Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer

Stevens-Johnsons syndrome (SJS) is a rare but life-threatening cutaneous adverse reaction mainly elicited by exposure to certain drugs. Here, we present a rare case of osimertinib-induced SJS that occurred when treating lung adenocarcinoma, with the SJS being confirmed by history, histopathology, and in vitro drug causality assessments.

Source: Lung Cancer - December 31, 2018 Category: Cancer & Oncology Authors: Yi-Tsz Lin, Chia-Yu Chu Source Type: research